Market Cap: $7.92M
SI
Soligenix, Inc.
SNGX
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $7.92M
Soligenix (Ticker: SNGX) is making significant strides in the development of a thermostable vaccine against the Bundibugyo virus, invaluable amidst the ongoing outbreak. Collaborating with Dr. Axel Le…
Soligenix Gains Ground with Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment Soligenix, Inc., a biopharmaceutical company dedicated to addressing unmet needs in rare diseases, achi…
Promising Pathway for Treating Behçet's Disease: Soligenix's SGX945 Receives PIM Designation Soligenix, Inc. announces a significant milestone in its commitment to developing treatments for rare disea…
Soligenix Advances Rare Disease Treatment with Orphan Drug Designation in Europe Soligenix, Inc., a biopharmaceutical company dedicated to developing therapies for rare diseases, secures a significant…
### Soligenix Advances Treating Rare Diseases with Dusquetide Designation Soligenix, Inc. emerges as a key player in the biopharmaceutical landscape focused on rare diseases, announcing a significant…
Soligenix outlines 2026 priorities around HyBryte confirmatory data FLASH2 confirmatory trial nears planned interim readout Soligenix is advancing HyBryte (synthetic hypericin) through a confirmatory…
Soligenix makes HyBryte the center of its 2026 strategy Soligenix, a late‑stage biopharmaceutical company focused on rare diseases, is concentrating 2026 efforts on advancing HyBryte (SGX301, syntheti…
Soligenix pushes confirmatory HyBryte™ study toward interim readout as design emphasizes longer treatment FLASH2 confirmatory trial centers on extended-treatment endpoint Soligenix is advancing its co…
Soligenix Advances Psoriasis Treatment with Promising Phase 2a Trial Results Soligenix, Inc. announces positive outcomes from the third cohort of its Phase 2a clinical trial for SGX302, a synthetic hy…
Soligenix Strengthens Advisory Board to Propel HyBryte™ Development for Rare Cancer Treatment Soligenix, Inc., a biopharmaceutical company focused on treatments for rare diseases, announces a strategi…
Soligenix Strengthens Medical Advisory Board to Propel HyBryte™ Development Soligenix, Inc., a biopharmaceutical company dedicated to developing treatments for rare diseases, announces a strategic enh…
Soligenix Strengthens Development Strategy with Expanded European Medical Advisory Board Soligenix, Inc., a late-stage biopharmaceutical firm devoted to developing treatments for rare diseases, takes…
Soligenix Strengthens Position in Rare Disease Treatments with Strategic Advisory Expansion Soligenix, Inc., a late-stage biopharmaceutical company specializing in treatments for rare diseases, is mak…
Soligenix Launches Public Offering to Fund Rare Disease Treatments Soligenix, Inc., a late-stage biopharmaceutical company dedicated to addressing rare diseases, announces a public offering of 5,555,5…
Soligenix Launches Public Offering to Fuel R&D in Rare Disease Treatments Soligenix, Inc., a biopharmaceutical company dedicated to developing therapies for rare diseases, announces a public offering…
Soligenix Welcomes Dr. Tomas J. Philipson as Strategic Advisor Soligenix, Inc., a biopharmaceutical firm dedicated to developing treatments for rare diseases, announces the appointment of Dr. Tomas J.…
Soligenix Strengthens Leadership with Strategic Advisor Appointment Soligenix, Inc. has recently announced the appointment of Dr. Tomas J. Philipson as a Strategic Advisor, a move that underscores the…
Soligenix Advances Ebolavirus Vaccine Stability: A Potential Game-Changer in Global Health Soligenix, Inc., a late-stage biopharmaceutical company focused on rare disease treatments, unveils groundbre…
Soligenix Advances ThermoVax® Technology for Vaccine Stability In a significant development, Soligenix, Inc. announces promising results from its collaboration with Dr. Axel Lehrer at the University o…
Soligenix Advances Vaccine Stability Through ThermoVax® Technology Soligenix, Inc., a biopharmaceutical company based in Princeton, N.J., is making significant strides in the field of vaccine developm…
Healthcare Sector Resilience Highlighted by Recent Momentum Gains In the rapidly evolving healthcare landscape, recent findings from the Benzinga Edge Ranking report spotlight the notable resilience a…
Healthcare Momentum: A Bright Spot in Soligenix's Growth Strategy In the ever-evolving landscape of the healthcare sector, Soligenix stands out as a company poised for significant growth, particularly…
Soligenix Advances in Rare Disease Treatment with FDA Orphan Drug Designation Soligenix, Inc. (SNGX) makes significant strides in the biotechnology field with the recent announcement that the U.S. Foo…
Soligenix Gains FDA Support for Rare Disease Treatment Soligenix, Inc. announces a pivotal development in its quest to address unmet medical needs in rare diseases. Recently, the U.S. Food and Drug Ad…
Soligenix Advances in Rare Disease Treatment with FDA Designation Soligenix, Inc. recently secures a significant milestone in its ongoing commitment to developing therapies for rare diseases, specific…